For instance, BRAF-V600E serves as a diagnostic cornerstone across multiple pathological subtypes of thyroid cancer and correlates with the therapeutic effectiveness of BRAF inhibitors such as vemurafenib and dabrafenib [34, 35]. Here, BRAF is linked to thyroid gland carcinoma.